A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising candidates for clinically useful antiviral agents. Studies using these compounds have highlighted the role of IN in both early and late stages of virus replication. However, dissecting the exact mechanism of action of the quinoline-based ALLINIs has been complicated by the multifunctional nature of these inhibitors because they both inhibit IN binding with its cofactor LEDGF/p75 and promote aberrant IN multimerization with similar potencies in vitro. Here we report design of small molecules that allowed us to probe the role of HIV-1 IN multimerization independently from IN-LEDGF/p75 interactions in infected cells. We altered the rigid quinoline moiety in ALLINIs and designed pyridine-based molecules with a rotatable single bond to allow these compounds to bridge between interacting IN subunits optimally and promote oligomerization. The most potent pyridine-based inhibitor, KF116, potently (EC50 of 0.024 µM) blocked HIV-1 replication by inducing aberrant IN multimerization in virus particles, whereas it was not effective when added to target cells. Furthermore, KF116 inhibited the HIV-1 IN variant with the A128T substitution, which confers resistance to the majority of quinoline-based ALLINIs. A genome-wide HIV-1 integration site analysis demonstrated that addition of KF116 to target or producer cells did not affect LEDGF/p75-dependent HIV-1 integration in host chromosomes, indicating that this compound is not detectably inhibiting IN-LEDGF/p75 binding. These findings delineate the significance of correctly ordered IN structure for HIV-1 particle morphogenesis and demonstrate feasibility of exploiting IN multimerization as a therapeutic target. Furthermore, pyridine-based compounds present a novel class of multimerization selective IN inhibitors as investigational probes for HIV-1 molecular biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Counterintuitively, the underlying mode of ALLINI action is not via inhibition of integration140,142,174–177,179–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MINI compounds moreover were ineffective at inhibiting the early stage of HIV-1 infection177.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“The common biochemical consequence of ALLINI binding is aberrant HIV-1 IN hyper-multimerization140,142,174–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“Compounds of the latter class do not effectively antagonise HIV-1 IN-LEDGF/p75 binding.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with the known role of LEDGF/p75 in HIV-1 integration targeting, genic integration targeting during HIV-1 ingress was suppressed by ALLINIs177,184,185.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915 · cited 1×
“Coot program [65] was used for the subsequent refinement and building of the structure.”
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742 · cited 1×
“Refmac5 [66] of the CCP4 package was used for the restraint refinement.”
MethodIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
Berne, B. J., & Pecora, R. (1976) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,856
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834 · cited 1×
“Replication competent HIV-1 was generated using pNL4-3 [68].”
MethodHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832 · cited 3×
“Since LEDGF/p75 is the primary cellular factor responsible for targeting HIV-1 integration to actively transcribed units [58,59], our findings indicate that the treatment of target cells with GS-B likely inhibits IN-LEDGF/p75 binding in the infected cells.”
BackgroundSelf-citationConnor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Research works printed but not linked: 4
- Brown PO (1997) Integration. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory. pp. 161–204.
- Fenwick CW, Tremblay S, Wardrop E, Bethell R, Coulomb R, <etal>et al</etal>.. (2011) Resistance Studies with HIV-1 Non-Catalytic Site Integrase Inhibitors. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies. Los Cabos, Mexico. pp. A9.
- Tsantrizos YS, Boes M., Brochu C., Fenwick C., Malenfant E., Mason S., Pesant M. (2007) Inhibitors of Human Immunodeficiency Virus Replication. International Patent Application PCT/CA2007/000845. pp. 1–116.
- Yoakim C, Bailey MD, Bilodeau F, Carson RJ, Fader L, <etal>et al</etal>.. (2010) Inhibitors of human immunodeficiency virus replication. International Patent Application PCT/CA2010/000707. pp. 1–195.
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor
Bester, S. M., Wei, G., Zhao, H., Adu-Ampratwum, D., Iqbal, N., Courouble, V. V., Francis, A. C., Annamalai, A. S., Singh, P. K., Shkriabai, N., et al. (2020) · Science · doi:10.1126/science.abb4808 · Cited by 239
Self-citationHIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis
Kessl, J. J., Kutluay, S. B., Townsend, D., Rebensburg, S., Slaughter, A., Larue, R. C., Shkriabai, N., Bakouche, N., Fuchs, J. R., Bieniasz, P. D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.044 · Cited by 152
Self-citationStructure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Vranckx, L. S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C., Battivelli, E., Verdin, E., Cereseto, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.039 · Cited by 113
HIV-1 Maturation: Lessons Learned from Inhibitors
Kleinpeter, A. B., & Freed, E. O. (2020) · Viruses · doi:10.3390/v12090940 · Cited by 119
“These compounds have been referred to in the literature as LEDGF/p75-IN interaction site inhibitors (LEDGINs) [176], noncatalytic site IN inhibitors [177], integrase-LEDGF allosteric inhibitors (INLAIs), multimeric IN inhibitors (MINIs) [178], or allosteric IN inhibitors (ALLINIs) [31,178,179].”
BackgroundAlternative modulation of protein–protein interactions by small molecules
Fischer, G., Rossmann, M., & Hyvönen, M. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.04.006 · Cited by 96
Cellular and molecular mechanisms of HIV-1 integration targeting
Engelman, A., & Singh, P. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2772-5 · Cited by 113
“ALLINI binding induces the formation of large integrase aggregates [191, 192, 202] through the bridging of neighboring protein molecules [203, 204].”
BackgroundFontana, J., Jurado, K. A., Cheng, N., Ly, N. L., Fuchs, J. R., Gorelick, R. J., Engelman, A. N., & Steven, A. C. (2015) · Journal of Virology · doi:10.1128/jvi.01522-15 · Cited by 96
Self-citationHost factors for retroviral integration site selection
Debyser, Z., Christ, F., Rijck, J. D., & Gijsbers, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.001 · Cited by 102
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
“In addition to ALLINI (168), such compounds have been referred to as LEDGIN for LEDGF-interaction site (167), NCINI for noncatalytic site IN inhibitor (165, 169), IN-LAI for IN-LEDGF allosteric inhibitor (170), and MINI for multimeric IN inhibitor (171).”
BackgroundInfluentialSec24C is an HIV-1 host dependency factor crucial for virus replication
Rebensburg, S. V., Wei, G., Larue, R. C., Lindenberger, J. J., Francis, A. C., Annamalai, A. S., Morrison, J. H., Shkriabai, N., Huang, S., KewalRamani, V. N., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00868-1 · Cited by 83
Self-citationMultiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif
Tesina, P., Čermáková, K., Hořejší, M., Procházková, K., Fábry, M., Sharma, S., Christ, F., Demeulemeester, J., Debyser, Z., Rijck, J. D., et al. (2015) · Nature Communications · doi:10.1038/ncomms8968 · Cited by 74
Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase
Gupta, K., Turkki, V., Sherrill-Mix, S., Hwang, Y., Eilers, G., Taylor, L., McDanal, C., Wang, P., Temelkoff, D., Nolte, R. T., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002584 · Cited by 68
Self-citationIntegrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis
Elliott, J. L., Eschbach, J. E., Koneru, P. C., Li, W., Puray-Chavez, M., Townsend, D., Lawson, D. Q., Engelman, A. N., Kvaratskhelia, M., & Kutluay, S. B. (2020) · eLife · doi:10.7554/elife.54311 · Cited by 59
“Eccentric virions generated via class II IN substitutions or ALLINI treatment are defective 93 for reverse transcription in target cells [10, 11, 17, 19-21, 23, 25-44, 48, 49, 51, 54, 58, 62] 94 despite containing equivalent levels of RT and vRNA genome as wild type (WT) particles [26, 95”
BackgroundSelf-citationHIV-1 Integrase Multimerization as a Therapeutic Target
Feng, L., Larue, R. C., Slaughter, A., Kessl, J. J., & Kvaratskhelia, M. (2015) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2015_439 · Cited by 45
“For example, replacing the rigid quinolone moiety with a more flexible pyridine-based structure in KF166 avoided the marked A128T resistance seen for quinolonebased ALLINIs (Sharma et al. 2014).”
BackgroundSelf-citationQuinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp
Zhao, J., Zhang, Y., Wang, M., Liu, Q., Lei, X., Wu, M. Y., Guo, S., Yi, D., Li, Q., Ma, L., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00083 · Cited by 58
Hu, S., Chen, J., Cao, J.-X., Zhang, S., Gu, S., & Chen, F.-E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106549 · Cited by 54
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
Self-citationGoing beyond Integration: The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
Elliott, J. L., & Kutluay, S. B. (2020) · Viruses · doi:10.3390/v12091005 · Cited by 51
Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase
Choi, E., Mallareddy, J. R., Lu, D., & Kolluru, S. (2018) · Future Science OA · doi:10.4155/fsoa-2018-0060 · Cited by 51
Bonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
“Consistently, INLAI resistance mutations at these positions were described following serial passage experiments, including known polymorphisms (Asn-124, Thr-124, and Ser-125) or novel substitutions (Asp-124, Ser-125, and Lys-125) (14, 41, 43).”
BackgroundInfluentialMaehigashi, T., Ahn, S., Kim, U.-I., Lindenberger, J. J., Oo, A., Koneru, P. C., Mahboubi, B., Engelman, A., Kvaratskhelia, M., Kim, K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009671 · Cited by 40
“Allosteric integrase inhibitors (ALLINIs) are a class of experimental anti-HIV agents that tar- get the noncatalytic sites of the viral integrase (IN) and interfere with the IN-viral RNA inter- action during viral maturation.”
BackgroundMethodInfluentialSelf-citationSlaughter, A., Jurado, K. A., Deng, N., Feng, L., Kessl, J. J., Shkriabai, N., Larue, R. C., Fadel, H. J., Patel, P. A., Jena, N., et al. (2014) · Retrovirology · doi:10.1186/s12977-014-0100-1 · Cited by 39
“rant IN multimerization during virus particle production and result in eccentric, non-infectious particles [44].”
BackgroundMethodSelf-citationFeng, L., Dharmarajan, V., Serrao, E., Hoyte, A., Larue, R. C., Slaughter, A., Sharma, A., Plumb, M. R., Kessl, J. J., Fuchs, J. R., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00167 · Cited by 37
“More recent efforts have led to the identification of allosteric IN inhibitors (ALLINIs, also called LEDGINs, NCINIs, INLAIs or MINIs) that bind in the clinically unexploited dimer interface of HIV-1 IN (22- 27).”
InfluentialSelf-citationDifferent Pathways Leading to Integrase Inhibitors Resistance
Thierry, E., Deprez, E., & Delelis, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02165 · Cited by 40
“Finally, they are also able to target the post-integrative steps leading to inactive viral particles formation with aberrant capsids (Balakrishnan et al., 2013; Sharma et al., 2014).”
BackgroundStrategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 41
Deng, N., Hoyte, A., Mansour, Y. E., Mohamed, M. S., Fuchs, J. R., Engelman, A. N., Kvaratskhelia, M., & Levy, R. (2016) · Protein Science · doi:10.1002/pro.2997 · Cited by 36
“1, red dashed oval), exhibit the highest potencies among ALLINIs.6,20 To understand how such extended functional groups interact with the CCD, we have docked ligand 80 into the LEDGF/p75 pocket at the CCD dimer interface; we found that the extended Rgroup is located outside the binding pocket and is largely solvent ex…”
BackgroundResultInfluentialSelf-citationMultimodal Functionalities of HIV-1 Integrase
Engelman, A., & Kvaratskhelia, M. (2022) · Viruses · doi:10.3390/v14050926 · Cited by 41
“Accordingly, viruses made from ALLINI-treated cells harbor a predominance of eccentric particles [7,58,176,210,223,224,226,229–231] and are defective for reverse transcription [58,140,176,210,223] due to preferential degradation of IN and vRNA in infected target cells [57,111].”
BackgroundInfluentialSelf-citationZhang, D., Yan, H.-L., Xu, X., Xu, L., Yin, Z., Chang, S., & Luo, H. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1743282 · Cited by 37
GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture
Bruggemans, A., Vansant, G., Balakrishnan, M., Mitchell, M. L., Cai, R., Christ, F., & Debyser, Z. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02328-20 · Cited by 35
“integrase inhibitors (MINIs) (46), and integrase-LEDGF allosteric inhibitors (INLAIs) (42).”
BackgroundMadison, M. K., Lawson, D. Q., Elliott, J., Ozantürk, A. N., Koneru, P. C., Townsend, D., Errando, M., Kvaratskhelia, M., & Kutluay, S. B. (2017) · Journal of Virology · doi:10.1128/jvi.00821-17 · Cited by 34
“less dense sucrose fractions due to the lack of vRNPs (24, 26), analysis of cores isolated”
BackgroundSelf-citationRetroviral Integrase: Then and Now
Andrake, M., & Skalka, A. M. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055043 · Cited by 38
Indole-based allosteric inhibitors of HIV-1 integrase
Patel, P. A., Kvaratskhelia, N., Mansour, Y. E., Antwi, J., Feng, L., Koneru, P. C., Kobe, M. J., Jena, N., Shi, G., Mohamed, M. S., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.037 · Cited by 36
Self-citationSynthesis and Evaluation of Aryl Quinolines as HIV-1 Integrase Multimerization Inhibitors
Jentsch, N. G., Hart, A. P., Hume, J. D., Sun, J., McNeely, K. A., Lama, C., Pigza, J. A., Donahue, M. G., & Kessl, J. J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00269 · Cited by 32
Self-citationExploring the Free-Energy Landscape and Thermodynamics of Protein-Protein Association
Tse, C., Wickstrom, L., Kvaratskhelia, M., Gallicchio, E., Levy, R. M., & Deng, N. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.08.005 · Cited by 34
“It is known that an ALLINI is required for the aberrant IN multimerization (6,38).”
BackgroundSelf-citationShkriabai, N., Dharmarajan, V., Slaughter, A., Kessl, J. J., Larue, R. C., Feng, L., Fuchs, J. R., Griffin, P. R., & Kvaratskhelia, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589572 · Cited by 30
“When added to target cells, ALLINIs block 3 -processing as well as reduce LEDGF/p75-mediated integration into active transcription units (39, 46).”
BackgroundSelf-citationHoyte, A. C., Jamin, A. V., Koneru, P. C., Kobe, M. J., Larue, R. C., Fuchs, J. R., Engelman, A. N., & Kvaratskhelia, M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816645 · Cited by 30
“Scalar increases of KF116 concentration in infected cells initially led to the single T124N IN substitution, which was detected after five passages in the presence of 10 M KF116 (13).”
BackgroundMethodInfluentialSelf-citationRashamuse, T. J., Harrison, A. T., Mosebi, S., van Vuuren, S. F., Coyanis, E. M., & Bode, M. L. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115210 · Cited by 30
Patel, D., Antwi, J., Koneru, P. C., Serrao, E., Forli, S., Kessl, J. J., Feng, L., Deng, N., Levy, R. M., Fuchs, J. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753384 · Cited by 30
“site at the distant CCD-CCD dimer interface in the principal LEDGF/p75 binding pocket (16-22).”
BackgroundSelf-citationJanssens, J., De Wit, F., Parveen, N., & Debyser, Z. (2022) · mBio · doi:10.1128/mbio.00007-22 · Cited by 28
“Since their initial discovery, compounds of different chemical nature but belonging to the same functional class have been described (26), including noncatalytic site integrase inhibitors (NCINIs) (27), allosteric integrase inhibitors (ALLINIs) (28), multimerization selective integrase inhibitors (MINIs) (29), and int…”
BackgroundWagstaff, K. M., Headey, S. J., Telwatte, S., Tyssen, D. P., Hearps, A. C., Thomas, D. R., Tachedjian, G., & Jans, D. A. (2018) · Cellular Microbiology · doi:10.1111/cmi.12953 · Cited by 28
“In fact, a new class of IN inhibitors selectively targeting multimerisation (Sharma et al., 2014) appear to interact with residues on both sides of the multimerisation interface, including Threonine 174, which was also strongly perturbed by all of our IN inhibiting compounds.”
BackgroundInfluentialKumar, D., Sharma, P., Shabu, Kaur, R., Lobe, M. M. M., Gupta, G. K., & Ntie‐Kang, F. (2021) · RSC Advances · doi:10.1039/d0ra10655k · Cited by 28
An Isoquinoline Scaffold as a Novel Class of Allosteric HIV-1 Integrase Inhibitors
Wilson, T. A., Koneru, P. C., Rebensburg, S. V., Lindenberger, J. J., Kobe, M. J., Cockroft, N. T., Adu‐Ampratwum, D., Larue, R. C., Kvaratskhelia, M., & Fuchs, J. R. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00633 · Cited by 27
Self-citationAligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs
Fader, L. D., Bailey, M., Beaulieu, E., Bilodeau, F., Bonneau, P., Bousquet, Y., Carson, R. J., Chabot, C., Coulombe, R., Duan, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00194 · Cited by 26
Uneven Genetic Robustness of HIV-1 Integrase
Rihn, S. J., Hughes, J., Wilson, S. J., & Bieniasz, P. D. (2014) · Journal of Virology · doi:10.1128/jvi.02451-14 · Cited by 26
“Surprisingly, these drugs exert their effect during HIV-1 production rather than during integration (where LEDGF acts), suggesting that they affect IN subunit interactions rather than LEDGF binding (84).”
BackgroundBennett, R. P., Salter, J. D., & Smith, H. C. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.004 · Cited by 24
“ALLINIs are small molecules that stabilize the multimeric interface of HIV integrase (IN) with low nanomolar IC50 values in antiviral assays [53].”
BackgroundAnderson-Daniels, J., Singh, P. K., Sowd, G. A., Li, W., Engelman, A. N., & Aiken, C. (2019) · Journal of Virology · doi:10.1128/jvi.01118-19 · Cited by 23
Amadori, C., van der Velden, Y. U., Bonnard, D., Orlov, I., van Bel, N., Le Rouzic, E., Miralles, L., Brias, J., Chevreuil, F., Spehner, D., et al. (2017) · Retrovirology · doi:10.1186/s12977-017-0373-2 · Cited by 22
“A new class of INinhibitors was designed that prevents this IN-LEDGF/ p75 interaction, named first LEDGINs [6], then ALLINIs [7] for Allosteric IN inhibitors, NCINIs [8–10] for non catalytic IN inhibitors, MINIs for Multimerization Integrase Inhibitors [11] or INLAIs for Integrase-LEDGF allosteric inhibitors [12].”
BackgroundHow to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli, A., Riva, V., Crespan, E., & Maga, G. (2017) · Biochemical Journal · doi:10.1042/bcj20160772 · Cited by 23
Delicado, T. L., Torrecilla, E., & Holguín, Á. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv333 · Cited by 21
Retroviral integrase: Structure, mechanism, and inhibition
Passos, D. O., Li, M., Craigie, R., & Lyumkis, D. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.007 · Cited by 22
“As with INSTIs, there are numerous ways in which resistance can occur, and several variants have been studied that arise to distinct drug classes [198,203,205,208,214,215,218].”
BackgroundResultInfluentialHIV-1 IN/Pol recruits LEDGF/p75 into viral particles
Desimmie, B. A., Weydert, C., Schrijvers, R., Vets, S., Demeulemeester, J., Proost, P., Paron, I., Rijck, J. D., Mast, J., Bannert, N., et al. (2015) · Retrovirology · doi:10.1186/s12977-014-0134-4 · Cited by 21
“Similar molecules were later reported by other groups [23-27].”
Gupta, K., Allen, A., Giraldo, C., Eilers, G., Sharp, R., Hwang, Y., Murali, H., Cruz, K., Janmey, P., Bushman, F., et al. (2021) · Structure · doi:10.1016/j.str.2020.12.001 · Cited by 19
“Over the past decade, a number of molecules have been developed that specifically target this proteinprotein interaction and display potent antiviral activity (Balakrishnan et al., 2013; Christ et al., 2012; Christ et al., 2010; Gupta et al., 2014; Jurado et al., 2013; Le Rouzic et al., 2013; Sharma et al., 2014; Tsia…”
BackgroundSelf-citationThe Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function
Singer, M. R., Dinh, T., Levintov, L., Annamalai, A. S., Rey, J. S., Briganti, L., Cook, N., Pye, V. E., Taylor, I. A., Kim, K., et al. (2023) · mBio · doi:10.1128/mbio.03560-22 · Cited by 21
“cells, these virions are unable to complete reverse transcription (11, 12, 15, 26, 28, 29).”
BackgroundMethodInfluentialSelf-citationThe C-Terminal Domain of HIV-1 Integrase: A Swiss Army Knife for the Virus?
Rocchi, C., Gouet, P., Parissi, V., & Fiorini, F. (2022) · Viruses · doi:10.3390/v14071397 · Cited by 19
Exploring HIV-1 Maturation: A New Frontier in Antiviral Development
McGraw, A., Hillmer, G., Mehedincu, S. M., Hikichi, Y., Gagliardi, S., Narayan, K., Tibebe, H., Marquez, D., Bose, L. M., Keating, A., et al. (2024) · Viruses · doi:10.3390/v16091423 · Cited by 20
Anti-HIV Agents: Current Status and Recent Trends
Geronikaki, A. A., Eleftheriou, P. T., & Poroikov, V. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_5001 · Cited by 17
Mugisha, C. S., Dinh, T., Kumar, A., Tenneti, K., Eschbach, J. E., Davis, K., Gifford, R. J., Kvaratskhelia, M., & Kutluay, S. B. (2022) · mBio · doi:10.1128/mbio.00431-22 · Cited by 18
“ALLINIs bind to a pocket within the CCD of IN (12, 61, 62, 65, 67 – 69) and induce the formation of open IN polymers by engaging the CTD of a nearby IN dimer (63).”
Self-citationBiological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
Bonnard, D., Rouzic, E. L., Singer, M. R., Yu, Z., Strat, F. L., Batisse, C., Batisse, J., Amadori, C., Chasset, S., Pye, V. E., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-23 · Cited by 17
“As shown for all other INLAIs (10, 12, 14, 21, 31), the small molecules engage the wellcharacterized pocket on the CCD dimerization interface, also implicated in the interaction with LEDGF/p75 IBD (38).”
BackgroundTargeting Virus-host Interactions of HIV Replication
Weydert, C., Rijck, J. D., Christ, F., & Debyser, Z. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150901115106 · Cited by 17
Zhang, F.-H., Debnath, B., Xu, Z.-L., Yang, L.-M., Song, L.-R., Zheng, Y., Neamati, N., & Long, Y. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.045 · Cited by 16
Jing, T., Shan, Z., Dinh, T., Biswas, A., Jang, S., Greenwood, J., Li, M., Zhang, Z., Gray, G., Shin, H. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64479-8 · Cited by 17
“…IN tetramers are the antiviral targets for investigational ALLINIs 29 , which are also known by alternative names such as LEDGF-IN site inhibitors (LEDGINs) 30 , IN-LEDGF allosteric inhibitors (INLAIs) 31,32 , multimerization IN inhibitors (MINIs) 33 , or noncatalytic IN inhibitors (NCINIs) 34,35 .”
Self-citationHIV-1 integrase binding to genomic RNA 5′-UTR induces local structural changes in vitro and in virio
Liu, S., Koneru, P. C., Li, W., Pathirage, C., Engelman, A., Kvaratskhelia, M., & Musier‐Forsyth, K. (2021) · Retrovirology · doi:10.1186/s12977-021-00582-0 · Cited by 16
Self-citationOhata, Y., Tomonaga, M., Watanabe, Y., Tomura, K., Kimura, K., Akaki, T., Adachi, K., Kodama, E. N., Matsuzaki, Y., & Hayashi, H. (2022) · Journal of Virology · doi:10.1128/jvi.01843-21 · Cited by 14
Naidu, B. N., Patel, M., McAuliffe, B. V., Ding, B., Cianci, C., Simmermacher, J., Jenkins, S., Parker, D. D., Sivaprakasam, P., Khan, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02169 · Cited by 14
CLIP-related methodologies and their application to retrovirology
Bieniasz, P. D., & Kutluay, S. B. (2018) · Retrovirology · doi:10.1186/s12977-018-0417-2 · Cited by 19
Optimized binding of substituted quinoline ALLINIs within the HIV-1 integrase oligomer
Sun, J., Patel, K., Hume, J. D., Pigza, J. A., Donahue, M. G., & Kessl, J. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100363 · Cited by 14
“A hallmark of this drug-induced defect is the mislocalization of ribonucleoprotein complexes (RNPs) to an eccentric position between the empty capsid (CA) core and the particle membrane in mature virions, whereas normal virions contain RNPs within the CA core.”
BackgroundMethodResultSelf-citationGenetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins
Troyano-Hernáez, P., Reinosa, R., & Holguín, Á. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.866705 · Cited by 16
Singh, P., Li, W., Bedwell, G., Fadel, H., Poeschla, E., & Engelman, A. (2022) · Viruses · doi:10.3390/v14091883 · Cited by 13
“These data ar consistent wit p ior reports that HIV-1 made in the presenc of ALLINI GS-B [54] and CX014442 [64] splayed baseli e frequencies of genic integr tion ta geting.”
BackgroundResultInfluentialSelf-citationSun, L., Gao, P., Zhan, P., & Liu, X. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1210127 · Cited by 13
Rashamuse, T. J., Fish, M. Q., Coyanis, E. M., & Bode, M. L. (2021) · Molecules · doi:10.3390/molecules26206203 · Cited by 13
Next-generation sequencing: A new avenue to understand viral RNA–protein interactions
Zhou, Y., Sotcheff, S. L., & Routh, A. L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101924 · Cited by 13
“The quinoline-based allosteric HIV-1 integrase inhibitors are a class of anti-HIV agents that bind noncatalytic sites of IN, preventing IN–vRNA interactions (105).”
Virus–Host Interactions in Retrovirus Integration
Engelman, A. N., & Maertens, G. N. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00004-2 · Cited by 12
Tang, W., Chang, Y.-H., Lin, C.-C., Jheng, J.-R., Hsieh, C.-F., Chin, Y., Chang, T.-Y., Lee, J., Liang, P., Lin, C.-Y., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00956-23 · Cited by 12
Imamichi, T., Bernbaum, J. G., Laverdure, S., Yang, J., Chen, Q., Highbarger, H., Hao, M., Sui, H., Dewar, R. L., Chang, W., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01323-21 · Cited by 12
The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario
Renzi, G., Carta, F., & Supuran, C. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512187 · Cited by 12
“Specifically, targeting the LEDGF/p75 interaction site affects the IN multimerization status, and thus, it allosterically affects its activity [117,118].”
BackgroundDinh, T., Tber, Z., Rey, J. S., Mengshetti, S., Annamalai, A. S., Haney, R., Briganti, L., Amblard, F., Fuchs, J. R., Cherepanov, P., et al. (2024) · mBio · doi:10.1128/mbio.00465-24 · Cited by 14
“3 containing WT or mutant INs as described (3, 38).”
Self-citationEilers, G., Gupta, K., Allen, A., Montermoso, S., Murali, H., Sharp, R. B., Hwang, Y., Bushman, F. D., & Duyne, G. D. V. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011097 · Cited by 11
“In contrast, the ALLINI KF116 [49] cannot be readily modeled in the interface of the ternary complex described here.”
Self-citationAgharbaoui, F. E., Hoyte, A. C., Ferro, S., Gitto, R., Buemi, M. R., Fuchs, J. R., Kvaratskhelia, M., & Luca, L. D. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.077 · Cited by 11
“The cytotoxicity assays were performed as described previously [28].”
BackgroundMethodSelf-citationLindenberger, J. J., Kobe, M., & Kvaratskhelia, M. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6eb2/pdb · Cited by 11
Self-citationOptimizing the Multimerization Properties of Quinoline-Based Allosteric HIV-1 Integrase Inhibitors
Sun, J., & Kessl, J. J. (2024) · Viruses · doi:10.3390/v16020200 · Cited by 12
“…and compound 75 [38]. in both WT and A128T structures revealed that the T128 mutation shifts the inhibitor slightly out of the binding pocket, even without any in both WT and A128T structures revealed that the T128 mutation shifts the inhibitor slightly out of the binding pocket, even without any”
BackgroundSelf-citationTargeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2
Hong, J.-Y., Lin, S., Kehn‐Hall, K., Zhang, K., Luo, S., Wu, H., Chang, S., & Hou, M. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.01.013 · Cited by 10
Multi-Substituted Quinolines as HIV-1 Integrase Allosteric Inhibitors
Dinh, L. P., Sun, J., Glenn, C. D., Patel, K., Pigza, J. A., Donahue, M. G., Yet, L., & Kessl, J. J. (2022) · Viruses · doi:10.3390/v14071466 · Cited by 10
“Previously, pyridine-based ALLINIs have been shown to overcome this resistance mutation by repositioning the scaffold away from the A128 IN residue while increasing contact points with the CCD dimer interface [18] (Figure 1, green and yellow IN monomers).”
BackgroundMethodResultSelf-citationWang, Y., Lin, H., Wang, P., Hu, J., Ip, T.-M., Yang, L.-M., Zheng, Y., & Wan, D. C. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00402 · Cited by 9
Cui, D., Zhang, B. W., Tan, Z., & Levy, R. M. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00740 · Cited by 11
Luca, L. D., Agharbaoui, F. E., Gitto, R., Buemi, M. R., Christ, F., Debyser, Z., & Ferro, S. (2016) · Molecular Informatics · doi:10.1002/minf.201501034 · Cited by 9
Pérez, A. A. M., Pérez, M. E. G., Robledo, A. I. U., Delgadillo‐Guzmán, D., Ruíz-Flores, P., & López-Márquez, F. C. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5444 · Cited by 9
“This suggests that HIV-1 infection, alone or in combination with cART, may induce OS, increasing the pathogenic effect (Hulgan et al. , Sharma et al. , 2014).”
InfluentialA Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor
Nakamura, T., Nakamura, T., Amano, M., Miyakawa, T., Yamagata, Y., Matsuoka, M., & Nakata, H. (2020) · Journal of Virology · doi:10.1128/jvi.00486-20 · Cited by 9
“17), integrase-LEDGF allosteric inhibitors (INLAIs) (18), or multimerization integrase inhibitors (MINIs) (19).”
BackgroundMethods for the Analyses of Inhibitor-Induced Aberrant Multimerization of HIV-1 Integrase
Kessl, J. J., Sharma, A., & Kvaratskhelia, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3046-3_10 · Cited by 9
“In this chapter, we describe three complementary methods designed in our laboratory to detect and quantify the effects of ALLINIs, MINIs, and related compounds on aberrant IN multi-merization both in vitro and within viral particles [29, 30].”
BackgroundMethodSelf-citationIdentification and Optimization of a Novel HIV-1 Integrase Inhibitor
Adu‐Ampratwum, D., Pan, Y., Koneru, P. C., Antwi, J., Hoyte, A. C., Kessl, J. J., Griffin, P. R., Kvaratskhelia, M., Fuchs, J. R., & Larue, R. C. (2022) · ACS Omega · doi:10.1021/acsomega.1c06378 · Cited by 8
Self-citationNew designs for HIV-1 integrase inhibitors: a patent review (2018-present)
Taoda, Y., Sugiyama, S., & Seki, T. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2178300 · Cited by 7
“Various names have been given to these inhibitors: noncatalytic site integrase inhibitors (NCINIs) [71], small molecules binding to the LEDGF/p75 binding site on integrase, (LEDGINs) [72], multimerization selective integrase inhibitors (MINIs) [32], allosteric integrase inhibitors (ALLINIs) [73], and integraseLEDGF/p7…”
BackgroundCyclic Hexapeptide Mimics of the LEDGF Integrase Recognition Loop in Complex with HIV‐1 Integrase
Northfield, S. E., Wielens, J., Headey, S. J., Williams‐Noonan, B. J., Mulcair, M. D., Scanlon, M. J., Parker, M. W., Thompson, P. E., & Chalmers, D. K. (2018) · ChemMedChem · doi:10.1002/cmdc.201800129 · Cited by 8
Kim, M., Ha, J.-H., Choi, J., Kim, B., Gapsys, V., Lee, K. O., Jee, J., Chakrabarti, K. S., de Groot, B. L., Griesinger, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01664 · Cited by 7
Sun, Q., Vijayan, R. S. K., Levy, R. M., & Deng, N. (2020) · Protein Science · doi:10.1002/pro.4004 · Cited by 7
“17–20 To delineate the different mechanisms by which ALLINIs act, derivatives that selectively target the aberrant multimerization have been designed.(21) More recently, Bonnard et al.”
BackgroundComplex of HIV-1 Integrase with Cellular Ku Protein: Interaction Interface and Search for Inhibitors
Ilgova, E., Galkin, S., Khrenova, M. G., Serebryakova, M. V., Gottikh, M., & Anisenko, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062908 · Cited by 7
“interaction, a family of allosteric inhibitors was recently developed and characterized, first called LEDGINs [12,13], and then ALLINIs for allosteric IN inhibitors [14], NCINIs for non-catalytic IN inhibitors [15,16], MINIs for multimerization integrase inhibitors [17], or INLAIs for integrase-LEDGF allosteric inhibi…”
BackgroundNew Polyketides and a Ferroptosis Inhibitor from the Marine-Derived Fungus Diaporthe searlei CS-HF-1
Xiao, J., Wu, P., Zhang, Y., Lv, Q., Chi, Y., Xu, W., Lin, W.-Z., & Cheng, Z. (2025) · Marine Drugs · doi:10.3390/md23100402 · Cited by 5
“…( 8 ) [44], 2,5-dimethylresorcin ( 9 ) [45], xylarolide ( 14) [40], asperlactone A ( 15 ) [42], phomolide D ( 16 ) [38], 4-hydroxy-3,6-dimethyl-2(1 H )-pyridinone ( 17 ) [46], and secalonic acid A ( 18 ) [37] by comparing the NMR data and specific rotations with those in the literature.”
Sanna, C., D’Abrosca, B., Fiorentino, A., Giammarino, F., Vicenti, I., Corona, A., Caredda, A., Tramontano, E., & Esposito, F. (2023) · Pharmaceuticals · doi:10.3390/ph16081118 · Cited by 6
Adachi, K., Manabe, T., Yamasaki, T., Suma, A., Orita, T., Furuzono, T., Adachi, T., Ohata, Y., Akiyama, Y., & Miyazaki, S. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129864 · Cited by 5
Metadata
- Authors
- Sharma, A., Slaughter, A., Jena, N., Feng, L., Kessl, J. J., Fadel, H. J., Malani, N., Male, F., Wu, L., Poeschla, E., Bushman, F. D., Fuchs, J. R., & Kvaratskhelia, M.
- Affiliations
- The Ohio State University (US)
- Mayo Clinic (US)
- University of Pennsylvania (US)
- Corresponding author
- Kvaratskhelia, Mamuka
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-29
- Volume
- 10
- Issue
- 5
- Pages
- e1004171
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC4038613
- OpenAlex
- W2044894228
- Cited by
- 124
- References
- 80
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 13 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 15 · 2015: 9 · 2014: 5
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Gilead Sciences
- National Institutes of Health (AI062520, GM103368)
- National Institute of General Medical Sciences (P50GM103368)
- National Institute of Allergy and Infectious Diseases (R01AI062520, R01AI077344, R01AI104483, R01AI052845, R01AI110310, R21AI110270)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase, integrase multimerization, LEDGF/p75, HIV-1 integration, antiviral drug design
- MeSH terms
- Antiviral Agents, Cell Line, Humans, Protein Binding, Quinolines, Virus Replication, HIV-1, Virus Integration, HIV Integrase, HIV Integrase Inhibitors, Intercellular Signaling Peptides and Proteins, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.